OFW
ALXN

Omnia Family Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

Omnia Family Wealth’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-84
Closed -$10K – 751
2017
Q1 		$10K Hold
84
– – ﹤0.01% 290
2016
Q4 		$10K Buy
+84
New +$10.3K 0.01% 293

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Omnia Family Wealth's ALXN Position: Q2 2017 in Review

Omnia Family Wealth sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 84 shares — an estimated $10K sold.

Omnia Family Wealth first reported a position in ALXN in Q4 2016 and held it in 2 quarters. The position peaked at $10K in Q1 2017. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Omnia Family Wealth reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Omnia Family Wealth sold 84 Alexion Pharmaceuticals shares in Q2 2017, an estimated $10K.
  • Omnia Family Wealth first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Omnia Family Wealth's Alexion Pharmaceuticals position peaked at $10K in Q1 2017.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Omnia Family Wealth's 13F filing for Q2 2017, filed 10 Aug 2017.